NEW YORK (GenomeWeb News) – The Armed Forces Institute of Pathology will use Calibrant Biosystems’ Gemini proteomics platform to validate biomarkers for brain cancer and to discover other predictive markers, the company said today.
Under a Cooperative Research and Development Agreement, AFIP, which is part of the US Department of Defense, will produce custom tissue microarrays in agreement with Calibrant’s specifications. The collaboration will focus initially on brain cancer with the ultimate goal of identifying predictive markers for personalized medicine, said Calibrant.
The Gemini platform is compatible with fresh and formalin-fixed archival tissues, allowing users to map protein networks between different cell types within one tissue section.
Michael Salgaller, COO of Gaithersburg, Md.-based Calibrant, said in a statement that the AFIP partnership is “an excellent way to conduct high-throughput validation on a large population set of carefully chosen samples.”
Financial terms of the agreement were not released.